LONDON, 18 September 2017:

Arix Bioscience plc (LSE: ARIX) (“Arix Bioscience”), a global healthcare and life science company supporting medical innovation, is pleased to note two positive press releases today by Autolus Limited (“Autolus”), an Arix Bioscience Group Business, announcing clinical progress across its portfolio.

The first release today from Autolus announced the completion of the first-dose cohort of its Phase I/II study of AUTO2, its novel, dual-targeted Chimeric Antigen Receptor (CAR) in patients with relapsed/refractory myeloma.

Autolus’ AUTO2 is a CAR-T cell therapy that targets both B-cell maturation antigen (BCMA) and transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI). AUTO2 re-programmes the patient’s own T cells to minimize the risk of cancer cells escaping treatment. AUTO2 is the first example of Autolus’ approach to unlocking the curative potential of CAR-T cell therapies.

The second release today from Autolus announced initiation of both the AMELIA and ALEXANDER Phase I/II studies for AUTO3, its novel, dual-targeting, AUTO3 CAR T cell therapy, for paediatric Acute Lymphocytic Leukaemia (ALL) and adult Diffuse Large B-Cell Lymphoma (DLBCL).

Autolus’ AUTO3 seeks to overcome two limitations of current therapies by introducing dual targeting CARs and addressing checkpoint mediated inhibition.

Joe Anderson, Chief Executive Officer of Arix Bioscience, commented: “Cell therapy has the potential to advance cancer treatment substantially and the announcements today from Autolus are an important step in this campaign. CAR-T is a proven, new approach to cancer treatment and Autolus has the science and the team to substantially advance this field, with a differentiated technology. We are privileged to work with the company and our co-investors to help advance these goals